AR049949A1 - Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol - Google Patents
Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolInfo
- Publication number
- AR049949A1 AR049949A1 ARP050102663A ARP050102663A AR049949A1 AR 049949 A1 AR049949 A1 AR 049949A1 AR P050102663 A ARP050102663 A AR P050102663A AR P050102663 A ARP050102663 A AR P050102663A AR 049949 A1 AR049949 A1 AR 049949A1
- Authority
- AR
- Argentina
- Prior art keywords
- dimethylamino
- phenol
- methylpropil
- etil
- crystaline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se relaciona con una forma, métodos para su preparacion y uso, y composiciones farmacéuticas que la contienen. Reivindicacion 1: Forma cristalina A del clorhidrato de (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol, caracterizada porque exhibe al menos líneas de rayos X (valores 2-q) en un diagrama de difraccion en polvos, cuando se miden por medio del uso de radiacion Cu Ka, a 15,1 +- 0,2; 16,0 +- 0,2; 18,9 +- 0,2; 20,4 +- 0,2 22,5 +- 0,2; 27,3 +- 0,2; 29,3 +- 0,2 y 30,4 +- 0,2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04015091A EP1612203B1 (en) | 2004-06-28 | 2004-06-28 | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049949A1 true AR049949A1 (es) | 2006-09-20 |
Family
ID=34925507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102663A AR049949A1 (es) | 2004-06-28 | 2005-06-28 | Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol |
ARP190102495A AR116052A2 (es) | 2004-06-28 | 2019-09-02 | Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102495A AR116052A2 (es) | 2004-06-28 | 2019-09-02 | Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol |
Country Status (27)
Country | Link |
---|---|
US (16) | US20070213405A1 (es) |
EP (2) | EP1612203B1 (es) |
JP (1) | JP4990764B2 (es) |
KR (1) | KR101096501B1 (es) |
CN (1) | CN1997621B (es) |
AR (2) | AR049949A1 (es) |
AT (2) | ATE368639T1 (es) |
AU (1) | AU2005256512B2 (es) |
BR (2) | BRPI0512792A (es) |
CA (1) | CA2572147C (es) |
CY (2) | CY1106929T1 (es) |
DE (2) | DE602004007905T2 (es) |
DK (2) | DK1612203T3 (es) |
EC (1) | ECSP17046065A (es) |
ES (2) | ES2291780T3 (es) |
HR (1) | HRP20110050T8 (es) |
IL (1) | IL180373A (es) |
MX (1) | MXPA06014741A (es) |
NO (3) | NO338605B1 (es) |
NZ (1) | NZ551605A (es) |
PE (1) | PE20060372A1 (es) |
PL (2) | PL1612203T3 (es) |
PT (2) | PT1612203E (es) |
RU (1) | RU2423345C2 (es) |
SI (2) | SI1612203T1 (es) |
WO (1) | WO2006000441A2 (es) |
ZA (1) | ZA200700774B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE602004007905T2 (de) * | 2004-06-28 | 2008-05-08 | Grünenthal GmbH | Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
PL2240431T3 (pl) * | 2007-12-07 | 2017-07-31 | Grünenthal GmbH | Krystaliczne modyfikacje (1R,2R)-3-(3-dimetyloamino-1-etylo-2-metyIopropylo)fenoIu |
RU2493830C2 (ru) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Лекарственная форма |
RU2508092C2 (ru) | 2008-05-09 | 2014-02-27 | Грюненталь Гмбх | Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки |
US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
BR112012001244A2 (pt) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
US20130116333A1 (en) | 2010-05-05 | 2013-05-09 | Ratiopharm Gmbh | Solid tapentadol in non-crystalline form |
RS61515B1 (sr) | 2010-07-23 | 2021-03-31 | Gruenenthal Gmbh | Soli ili kokristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola |
AU2011297892B2 (en) | 2010-09-02 | 2014-05-29 | Grunenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
PL2680832T3 (pl) | 2011-03-04 | 2020-03-31 | Grünenthal GmbH | Wodna formulacja farmaceutyczna tapentadolu do podawania doustnego |
KR102039320B1 (ko) | 2011-03-04 | 2019-11-01 | 그뤼넨탈 게엠베하 | 타펜타돌을 함유하는 반고체 수성 약제학적 조성물 |
EA024193B1 (ru) * | 2011-03-04 | 2016-08-31 | Грюненталь Гмбх | Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
CA2839126A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
WO2013111161A2 (en) * | 2012-01-10 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof |
WO2013120466A1 (en) | 2012-02-17 | 2013-08-22 | Zentiva, K.S. | A new solid form of tapentadol and a method of its preparation |
WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
LT2838512T (lt) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CZ304576B6 (cs) * | 2012-07-24 | 2014-07-16 | Zentiva, K.S. | Oxalát TAPENTADOLU a způsob jeho přípravy |
CN102924303B (zh) * | 2012-10-31 | 2013-11-20 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
US9599565B1 (en) * | 2013-10-02 | 2017-03-21 | Ondax, Inc. | Identification and analysis of materials and molecular structures |
WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
GB2523089A (en) * | 2014-02-12 | 2015-08-19 | Azad Pharmaceutical Ingredients Ag | Stable polymorph form B of tapentadol hydrochloride |
MX2016014738A (es) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
AU2016239772B2 (en) | 2015-03-27 | 2021-05-13 | Grünenthal GmbH | Stable formulation for parenteral administration of Tapentadol |
MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
ES2772806T3 (es) | 2016-04-19 | 2020-07-08 | Ratiopharm Gmbh | Fosfato de tapentadol cristalino |
PE20190908A1 (es) | 2016-09-23 | 2019-06-26 | Gruenenthal Chemie | Formulacion estable para la administracion parenteral de tapentadol |
WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
US11492342B2 (en) | 2020-11-03 | 2022-11-08 | Landos Biopharma, Inc. | Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
ATE228117T1 (de) * | 1996-08-14 | 2002-12-15 | Searle & Co | Kristalline form von 4-(5-methyl-3-phenylisoxazol-4-yl)benzolsulfona id |
AU2002212340B2 (en) * | 2000-10-31 | 2006-12-14 | Sandoz Ag | Crystalline forms of venlafaxine hydrochloride |
US20050176790A1 (en) | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
DK1426355T3 (da) * | 2001-09-13 | 2009-02-23 | Kissei Pharmaceutical | Krystaller af hydroxynorephedrinderivater |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
DE602004007905T2 (de) * | 2004-06-28 | 2008-05-08 | Grünenthal GmbH | Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
-
2004
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de active Active
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
- 2004-06-28 EP EP04015091A patent/EP1612203B1/en active Active
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es active Active
-
2005
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en active Active
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja active Active
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko active Protection Beyond IP Right Term
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en unknown
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en active Application Filing
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 CA CA2572147A patent/CA2572147C/en active Active
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 EP EP05770026A patent/EP1799633B1/en active Active
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es active Active
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de active Active
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
-
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
-
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
-
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
-
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en active Active
-
2011
- 2011-01-24 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
-
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
-
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
-
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
-
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
-
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
-
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
-
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es unknown
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
-
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
-
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
-
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049949A1 (es) | Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
AR112227A2 (es) | Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma | |
JO2793B1 (en) | The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains | |
CR8647A (es) | Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen | |
BRPI0804994A2 (pt) | forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a | |
BRPI0603043A (pt) | forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a | |
AR052925A1 (es) | Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
CL2017001249A1 (es) | Forma cristalina de sulfato de hidrógeno (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidinaa-1-il)-pirazolo[1,5-a] pirimidinaa-3-il)-3-hidroxipirrolidinaa-1-carboxamida. | |
AR054777A1 (es) | Modificaciones cristalinas de piraclostrobina | |
AR029570A1 (es) | Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
BRPI0603074A (pt) | forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a | |
AR053147A1 (es) | Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
BRPI0604250A (pt) | forma cristalina delta de cloridrato de ivabradina, processo para sua preparação e composições farmacêuticas contendo a mesma | |
UA86595C2 (ru) | Гамма-кристаллическая форма гидрохлорида ивабрадина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
AR029571A1 (es) | Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
TW200501965A (en) | Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle | |
PE20130212A1 (es) | Formas polimorficas de st-246 y metodos de preparacion | |
ECSP10010078A (es) | Co-cristales de pirimetanilo y ditianona | |
EA200401515A1 (ru) | Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а | |
PE20050766A1 (es) | Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen | |
BRPI0602206A (pt) | forma polimórfica de dexcetoprofeno trometamol, sua preparação e composições que a contêm | |
EP4238966A4 (en) | TETRAHYDRONAPHTHALIN COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
CL2008003412A1 (es) | Uso de compuestos no beta-oxidables de formula r"-coo-(ch2)2n+1-x-r para preparar una composicion nutricional y/o farmaceutica par inhibir la maduracion sexual de peces. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |